Emcure Pharmaceuticals Limited (NSE:EMCURE)
1,440.70
-43.90 (-2.96%)
Jan 28, 2026, 1:40 PM IST
Emcure Pharmaceuticals Revenue
Emcure Pharmaceuticals had revenue of 22.70B INR in the quarter ending September 30, 2025, with 13.38% growth. This brings the company's revenue in the last twelve months to 84.49B, up 16.44% year-over-year. In the fiscal year ending March 31, 2025, Emcure Pharmaceuticals had annual revenue of 78.96B with 18.59% growth.
Revenue (ttm)
84.49B
Revenue Growth
+16.44%
P/S Ratio
3.33
Revenue / Employee
12.55M
Employees
6,731
Market Cap
281.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 78.96B | 12.38B | 18.59% |
| Mar 31, 2024 | 66.58B | 6.72B | 11.23% |
| Mar 31, 2023 | 59.86B | 1.30B | 2.23% |
| Mar 31, 2022 | 58.55B | 8.22B | 16.33% |
| Mar 31, 2021 | 50.33B | -150.80M | -0.30% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Glenmark Pharmaceuticals | 159.97B |
| Ipca Laboratories | 93.59B |
| Piramal Pharma | 89.36B |
| Alembic Pharmaceuticals | 70.83B |
| Laurus Labs | 67.22B |
| Gland Pharma | 58.01B |
| Ajanta Pharma | 49.73B |
| NATCO Pharma | 43.90B |